NASDAQ · CUE
Healthcare · Biotechnology
$27.66
Up+$5.33 (+23.87%)
Updated Oct 10, 2026, 11:06 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CUE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
CUE closed at $27.66 after 21 trading sessions, down 3.76% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $22.21 | $29.00 | $22.10 | $27.66 | 394.64K |
| Oct 8, 2026 | $22.38 | $22.7422 | $21.60 | $22.33 | 109.9K |
| Oct 7, 2026 | $22.92 | $23.10 | $22.27 | $22.51 | 133.17K |
| Oct 6, 2026 | $24.22 | $24.89 | $22.92 | $23.14 | 174.85K |
| Oct 5, 2026 | $25.60 | $25.94 | $22.21 | $24.36 | 272.65K |
| Oct 2, 2026 | $25.60 | $25.92 | $24.67 | $25.57 | 157.04K |
| Oct 1, 2026 | $26.00 | $26.025 | $24.60 | $25.25 | 183.43K |
| Sep 30, 2026 | $25.89 | $27.43 | $24.88 | $25.87 | 228.12K |
| Sep 29, 2026 | $28.15 | $28.15 | $24.13 | $25.51 | 283.9K |
| Sep 28, 2026 | $30.86 | $32.0682 | $27.01 | $27.45 | 237.83K |
| Sep 25, 2026 | $33.12 | $33.40 | $30.75 | $31.41 | 232.44K |
| Sep 24, 2026 | $31.15 | $33.635 | $30.435 | $32.85 | 330.4K |
| Sep 23, 2026 | $29.91 | $35.23 | $29.86 | $31.71 | 696.48K |
| Sep 22, 2026 | $28.61 | $32.39 | $25.49 | $30.90 | 1.21M |
| Sep 21, 2026 | $38.50 | $41.50 | $23.80 | $28.27 | 3.54M |
| Sep 18, 2026 | $39.35 | $41.00 | $35.535 | $37.05 | 381.95K |
| Sep 17, 2026 | $34.75 | $38.07 | $34.20 | $37.84 | 195.08K |
| Sep 16, 2026 | $31.27 | $36.469 | $30.325 | $34.17 | 277.39K |
| Sep 15, 2026 | $30.65 | $32.00 | $29.26 | $31.64 | 127.17K |
| Sep 14, 2026 | $28.24 | $31.10 | $28.24 | $30.55 | 136.6K |
| Sep 11, 2026 | $28.38 | $28.89 | $27.50 | $28.74 | 122.77K |
The latest Smart Investors Daily articles mentioning CUE.
Company
Market Activity
Research & News
CUE research
Company profile and research snapshot.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | B. Riley Securities | Buy | — |
| Aug 25, 2025 | LUCID CAPITAL MARKETS | Buy | — |
| Apr 2, 2025 | Citizens Capital Markets | Market Outperform | — |
| Aug 20, 2024 | Stifel | Buy | — |
| Jul 26, 2024 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 28, 2026
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate
Yahoo · Sep 26, 2026
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines. At week 12, complete hive resolution occurred in 54% of patients receiving 4 mg/kg CUE-221 versus 11% […]
SeekingAlpha · Sep 24, 2026
2026-09-24. The following slide deck was published by Cue Biopharma, Inc.
Yahoo · Sep 21, 2026
Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CUE.
